Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMKX003142 in Rapidly Progressive ADPKD
NCT06800651Phase 2Recruiting
- Sponsor
- Jemincare
- Start
- Mar 2025
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autosomal dominant polycystic kidney disease (ADPKD) comparing JMKX003142 with Placebo (2 arms). Primary endpoint: Percentage Change of Total Kidney Volume at 52 weeks. Started Mar 2025; status: recruiting.
02
Drugs
JMKX003142
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT06800651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06800651.